Discovery of Novel SIRT3 Inhibitors for the Cancer Differentiation Therapy by Structural Modification

• Published in: Drug development research Vol. 85; no. 7; pp. e70016 - n/a
• Main Authors: Li, Honggang, Du, Yanmei, Zhang, Lihui, Xu, Guangzhao, Li, Fahui, Zhang, Daopeng, Zhang, Lei
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc 01-11-2024
• Subjects: Apoptosis; Cancer; Cancer therapies; Cell differentiation; Cell proliferation; Chemical synthesis; differentiation; Differentiation (biology); Growth factors; Inhibitors; Lead compounds; Multiple myeloma; Phenotypes; selective inhibitor; SIRT3; structural modification; Therapy
• ISSN: 0272-4391; 1098-2299; 1098-2299
• DOI: 10.1002/ddr.70016

ABSTRACT
Inhibition of SIRT3 triggered differentiation of multiple myeloma (MM) cells. In discovery of potent SIRT3 inhibitors for cancer differentiation therapy, structural modification was performed on the previously developed lead compound S27. A total of 49 compounds divided into two series were designed and synthesized. In the enzyme inhibitory assay, several molecules (A7, A13, B15, and B26) exhibited potent SIRT3 inhibitory activity and selectivity. Significantly, representative compounds, especially A7, promoted differentiation of MM cells from cancer phenotype to normal cells, accompanied by increased expression of antigen CD49e, human immunoglobulin light chain λ‐IgLG and κ‐IgLG. Additionally, molecule A7 reversed growth factor IL‐6 induced MM cell proliferation, improved the antiproliferative activity of Ixazomib and increased the apoptotic rate of MM cells treated with Ixazomib. Collectively, potent SIRT3 inhibitors with MM cell differentiation potency were developed for the cancer therapy used alone or in combination.